Optirize (Risedronate Sodium)

Risedronate sodium is indicated for several bone‑remodeling disorders where inhibition of bone resorption is required.

• Osteoporosis: reduces the risk of vertebral and hip fractures in post‑menopausal women and men.
• Paget’s disease of bone: normalises bone turnover and alleviates bone pain.
• Glucocorticoid‑induced osteoporosis: helps maintain bone density in patients receiving long‑term corticosteroid therapy.
• Osteogenesis imperfecta (adult patients): improves bone mineral density and reduces fracture incidence.

• Risedronate sodium binds with high affinity to hydroxy‑apatite crystals at sites of active bone remodeling. When osteoclasts attach to these crystal surfaces, the drug is internalised, inhibiting farnesyl pyrophosphate synthase within the mevalonate pathway, which impairs osteoclast function and induces apoptosis, thereby reducing bone resorption.

Adverse reactions to risedronate sodium are generally dose‑related and may vary in severity.

Common Side Effects

• Upper gastrointestinal irritation: dyspepsia, abdominal discomfort.
• Nausea and vomiting.
• Musculoskeletal pain: bone, joint or muscle aches.
• Headache.
• Transient flu‑like symptoms.

Serious or Rare Side Effects

• Osteonecrosis of the jaw (ONJ).
• Atypical femoral fractures.
• Severe esophagitis or esophageal ulceration.
• Acute phase reactions with fever and myalgia.
• Hypocalcaemia.
• Renal impairment (acute kidney injury).

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters.

• Renal function: evaluate creatinine clearance before starting and periodically thereafter.
• Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk.
• Gastro‑intestinal health: advise patients to take the tablet with a full glass of water and remain upright for at least 30 minutes.
• Concomitant medications: review for drugs that may affect absorption or increase renal load.
• Pregnancy and lactation: avoid use unless clearly indicated; discuss risks with the prescriber.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Risedronate sodium may interact with several medicines, altering its absorption or renal handling.

Major Interactions (Avoid)

• Calcium carbonate or other calcium supplements taken concurrently: markedly reduces oral absorption of risedronate.
• Antacids containing aluminium or magnesium: impair drug uptake when taken within the same hour.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients with compromised renal function: increase risk of renal adverse events.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors (PPIs): may modestly reduce absorption; monitor therapeutic response.
• Loop diuretics: can exacerbate hypocalcaemia; check serum calcium levels.
• Corticosteroids: may counteract bone‑protective effects; assess bone density periodically.